Akero Therapeutics voluntarily prepays $37.6M loan with Hercules Capital, terminates loan agreement

Akero Therapeutics, Inc.

Voluntarily prepaid $37.6M in aggregate to Hercules Capital to fully satisfy and discharge all obligations under Loan Agreement dated June 2022.
Loan originally provided up to $150M; company had borrowed $35M. Interest rate variable (greater of 7.65% or prime plus 3.65%).
Interest-only payments due through Jan 1, 2026; principal payments would have started after, with maturity March 1, 2027.
Termination of loan agreement and related documents; warrants from original agreement remain outstanding.

item 1.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.